Evaluation of vitamin D supplementation on outcome of patients with ventilator associated pneumonia

Phase 2

Conditions: Condition 1: ventilator associated pneumonia. Condition 2: ventilator associated pneumonia. Condition 3: ventilator associated pneumonia. Condition 4: ventilator associated pneumonia. Condition 5: ventilator associated pneumonia. Condition 6: ventilator associated pneumonia.
Pneumonia due to Streptococcus pneumoniae
Pneumonia due to other infectious organisms, not elsewhere classified
Pneumonia due to Haemophilus influenzae
Bacterial pneumonia, not elsewhere classified
Pneumonia in diseases classified elsewhere
Pneumonia, organism unspecified

Registration Number: IRCT2014112920134N1

Lead Sponsor: Chancellor for research, shahid beheshti medical university

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 46

Inclusion Criteria

Patients over 18 years old, that clinically and based on the following criteria have been diagnosed with VAP (During the first 48 hours of diagnosis): The presence of new or progressive infiltration on the patient's chest radiograph that occur 48-72 hours after initiation of mechanical ventilation, While two of the following symptoms must be present with it: Fever over 38 ° C; leukocytosis or leukopenia (white blood cell count greater than 12,000 per µL of blood or less than 4000 per µL blood) and purulent pulmonary secretions.

Exclusion criteria: Stage3 or more chronic kidney problems; liver problems with CHILD-PUGH stage B or C; history of cancer within the last 3 months, or currently taking chemotherapy drugs; patients with immune deficiency; pancreatitis; other infections, concurrently with pneumonia caused by mechanical ventilation, patients with VAP that the vitamin D levels are normal and Coagulopathy.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Procalcitonin plasma level. Timepoint: Day 1 and 7 of study. Method of measurement: Plasma level that measured with electrochemiluminescence and reported as ng/ml.;C-reactive protein plasma level. Timepoint: Day 1 and 7 of study. Method of measurement: Plasma level that measured with elisa kit and reported as mg/L.;Interleukin-6 plasma level. Timepoint: Day 1 and 7 of study. Method of measurement: Plasma level that measured with elisa kit and reported as pg/ml.;Vitamin D plasma level. Timepoint: Day 1 and 7 of study. Method of measurement: Plasma level that measured with elisa kit and reported as ng/ml.

Secondary Outcome Measures